Th17 and allergy

Allergology International

Volumn 57, Issue 2, 2008, Pages 121-134

  Oboki, Keisuke ^a   Ohno, Tatsukuni ^a   Saito, Hirohisa ^a,b   Nakae, Susumu ^a,b,c  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Allergy; IL 17; Th17

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; CYTOKINE; CYTOKINE ANTIBODY; ETHYLENE DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; OVALBUMIN; OXAZOLONE; TOLUENE DIISOCYANATE; TUMOR NECROSIS FACTOR;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ARTHRITIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL TRANSFER; CONJUNCTIVITIS; CONTACT ALLERGY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME SYNTHESIS; EOSINOPHIL; FOOD ALLERGY; HELPER CELL; HUMAN; MAST CELL; METHODOLOGY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; SKIN ALLERGY; TH17 CELL; TH2 CELL;

EID: 46049111181     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.R-07-160     Document Type: Review

References (147)

1. Parronchi P, Brugnolo F, Sampognaro S, Maggi E. Genetic and environmental factors contributing to the onset of allergic disorders. Int. Arch. Allergy Immunol. 2000; 121:2-9.
2. Valenta R, Ball T, Focke M et al. Immunotherapy of allergic disease. Adv. Immunol. 2004;82:105-153.
3. Saarinen UM. Transfer of latent atopy by bone marrow transplantation? A case report. J Allergy Clin. Immunol. 1984;74:196-200.
4. Agosti JM, Sprenger JD, Lum LG et al. Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. N. Engl. J. Med. 1988;319:1623-1628.
5. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986;136:2348-2357.
6. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl. J. Med. 2002;347:911-920.
7. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
8. Ferber IA Brocke S, Taylor-Edwards C et al. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol. 1996;156:5-7.
9. Krakowski M, Owens T. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 1996;26:1641-1646.
10. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 1996;157:3223-3227.
11. Manoury-Schwartz B, Chiocchia G, Bessis N et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-γ receptors. J. Immunol. 1997;158:5501-5506.
12. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A Matthys P. Accelerated collagen-induced arthritis in IFN-γ receptor-deficient mice. J. Immunol. 1997;158:5507-5513.
13. Caspi RR, Chan CC, Grubbs BG et al. Endogenous systemic IFN-γ has a protective role against ocular autoimmunity in mice. J. Immunol. 1994;152:890-899.
14. Jones LS, Rizzo LV, Agarwal RK et al. IFN-γ-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J. Immunol. 1997;158:5997-6005.
15. Ring GH, Dai Z, Saleem S, Baddoura FK, Lakkis FG. Increased susceptibility to immunologically mediated glomerulonephritis in IFN-γ-deficient mice. J. Immunol. 1999;163:2243-2248.
16. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 2000;165:6107-6115.
17. Nakae S, Komiyama Y, Nambu A et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002;17:375-387.
18. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL 17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. U. S. A. 2003;100:5986-5990.
19. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003;278:1910-1914.
20. Murphy CA, Langrish CL, Chen Y et al. Divergent proand antiinflammatory roles for IL-23 and IL12 in joint autoimmune inflammation. J. Exp. Med. 2003;198:1951-1957.
21. Nakae S, Nambu A Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 2003;171:6173-6177.
22. Langrish CL, Chen Y, Blumenschein WM et al. IL23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005;201:233-240.
23. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005;6:1123-1132.
24. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005;6:1133-1141.
25. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of TL-17-producing T cells. Immunity 2006;24:179- 189.
26. Mangan PR, Harrington LE, O'Quinn DB et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 2006;441:231-234.
27. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
28. + T helper cells. Cell 2006;126:1121-1133.
29. Zhou L, Ivanov II, Spolski R et al. IL6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL23 pathways. Nat. Immunol. 2007;8:967-974.
30. Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 2007;448:484- 487.
31. Nurieva R, Yang XO, Martinez G et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007;448:480-483.
32. McGeachy MJ, Bak-Jensen KS, Chen Y et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat. Immunol. 2007;8:1390-1397.
33. Stumhofer JS, Laurence A, Wilson EH et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 2006;7:937-945.
34. Batten M, Li J, Yi S et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 2006;7:929-936.
35. Stumhofer JS, Silver JS, Laurence A et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 2007;8:1363-1371.
36. Fitzgerald DC, Zhang GX, El-Behi M et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 2007;8:1372- 1379.
37. Awasthi A, Carrier Y, Peron JP et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 2007;8:1380-1389.
38. Niedbala W, Wei XQ, Cai B et al. IL35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 2007;37:3021-3029.
39. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-569.
40. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 2007;8:950-957.
41. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007;8:942-949.
42. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 1999;17:255-281.
43. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu. Rev. Immunol. 2004;22:789-815.
44. Wong CK, Ho CY, Ko FW et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin. Exp. Immunol. 2001;125:177- 183.
45. Molet S, Hamid Q, Davoine F et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J. Allergy Clin. Immunol. 2001;108:430-438.
46. Laan M, Palmberg L, Larsson K, Linden A. Free, soluble interleukin-17 protein during severe inflammation in human airways. Eur. Respir. J. 2002;19:534-537.
47. Barczyk A, Pierzchała W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir. Med. 2003;97:726-733.
48. Chakir J, Shannon J, Molet S et al. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression. J. Allergy Clin. Immunol. 2003;111:1293-1298.
49. Sun YC, Zhou QT, Yao WZ. Sputum interleukin-17 is increased and associated with airway neutrophilia in patients with severe asthma. Chin. Med. J. 2005;118:953-956.
50. Bullens DM, Truyen E, Coteur L et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir. Res. 2006;7:135.
51. Laan M, Lotvall J, Chung KF, Linden A. IL17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. Br. J. Pharmacol. 2001;133:200-206.
52. Kawaguchi M, Kokubu F, Kuga H et al. Modulation of bronchial epithelial cells by IL-17. J. Allergy Clin. Immunol. 2001;108:804- 809.
53. Jones CE, Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-α, and granulocyte-colony- stimulating factor by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2002;26:748-753.
54. Prause O, Laan M, Lotvall J, Linden A. Pharmacological modulation of interleukin-17-induced GCP-2-, GRO-α- and interleukin-8 release in human bronchial epithelial cells. Eur. J. Pharmacol. 2003;462:193-198.
55. Chen Y, Thai P, Zhao YH, Ho YS, DeSouza MM, Wu R. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J. Biol. Chem. 2003;278:17036-17043.
56. Kao CY, Chen Y, Thai P et al. IL-17 markedly up-regulates β-defensin-2 expression in human airway epithelium via JAK and NF-κB signaling pathways. J. Immunol. 2004;173:3482-3491.
57. Kao CY, Huang F, Chen Y et al. Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kB-dependent signaling pathway. J. Immunol. 2005;175:6676-6685.
58. Vanaudenaerde BM, Wuyts WA, Dupont LJ, Van Raemdonck DE, Demedts MM, Verleden GM. Interleukin-17 stimulates release of interleukin-8 by human airway smooth muscle cells in vitro: a potential role for interleukin-17 and airway smooth muscle cells in bronchiolitis obliterans syndrome. J. Heart Lung Transplant 2003;22:1280-1283.
59. Henness S, Johnson CK, Ge Q, Armour CL, Hughes JM, Ammit AJ. IL-17A augments TNF-α-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability. J. Allergy Clin. Immunol. 2004;114:958- 964.
60. Laan M, Cui ZH, Hoshino H et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 1999;162:2347-2352.
61. Hoshino H, Lotvall J, Skoogh BE, Linden A. Neutrophil recruitment by interleukin-17 into rat airways in vivo. Role of tachykinins. Am. J. Respir. Crit. Care Med. 1999;159:1423-1428.
62. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. 1995;95:843-852.
63. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997;156:737-743.
64. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 1999;160:1001-1008.
65. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. 1999;160:1532-1539.
66. Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance. Am. J. Respir. Crit. Care Med. 2000;161:1185-1190.
67. Amin K, Ludviksdottir D, Janson C et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am. J. Respir. Crit. Care Med. 2000;162:2295-2301.
68. Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001;119:1329-1336.
69. Gold DR, Fuhlbrigge AL. Inhaled corticosteroids for young children with wheezing. N. Engl. J. Med. 2006;354:2058-2060.
70. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002;57:643-648.
71. Lloyd CM, Gonzalo JA, Coyle AJ, Gutierrez-Ramos JC. Mouse models of allergic airway disease. Adv. Immunol. 2001;77:263-295.
72. Moffatt JD. What targets have knockouts revealed in asthma? Pharmacol. Ther. 2005;107:343-357.
73. Takeda K, Hamelmann E, Joetham A et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J. Exp. Med. 1997;186:449-454.
74. Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J. Exp. Med. 2000;192:455-462.
75. Korsgren M, Erjefalt JS, Korsgren O, Sundler F, Persson CG. Allergic eosinophil-rich inflammation develops in lungs and airways of B cell-deficient mice. J. Exp. Med. 1997;185:885-892.
76. Mayr SI, Zuberi RI, Zhang M et al. IgE-dependent mast cell activation potentiates airway responses in murine asthma models. J. Immunol. 2002;169:2061-2068.
77. Nakae S, Komiyama Y, Yokoyama H et al. IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int. Immunol. 2003;15:483-490.
78. Schmitz N, Kurrer M, Kopf M. The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur. J. Immunol. 2003;33:991-1000.
79. Nakae S, Lunderius C, Ho LH, Schafer B, Tsai M, Galli SJ. TNF can contribute to multiple features of ovalbumin-induced allergic inflammation of the airways in mice. J Allergy Clin. Immunol. 2007;119:680-686.
80. Chung CD, Kuo F, Kumer J et al. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J. Immunol. 2003;170:581-587.
81. Goya I, Villares R, Zaballos A et al. Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. J. Immunol. 2003;170:2138-2146.
82. Gonzalo JA, Qiu Y, Lora JM et al. Coordinated involvement of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1: CCR8 axis. J. Immunol. 2007;179:1740-1750.
83. Wilder JA, Collie DD, Wilson BS, Bice DE, Lyons CR, Lipscomb MF. Dissociation of airway hyperresponsiveness from immunoglobulin E and airway eosinophilia in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 1999;20:1326-1334.
84. Rudmann DG, Moore MW, Tepper JS et al. Modulation of allergic inflammation in mice deficient in TNF receptors. Am. J. Physiol. Lung Cell Mol. Physiol. 2000;279:L1047-1057.
85. Broide DH, Stachnick G, Castaneda D, Nayar J, Sriramarao P. Inhibition of eosinophilic inflammation in allergen-challenged TNF receptor p55/p75 - and TNF receptor p 55-deficient mice. Am. J. Respir. Cell Mol. Biol. 2001;24:304-311.
86. Kanehiro A, Lahn M, Makela MJ et al. Tumor necrosis factor-α negatively regulates airway hyperresponsiveness through γδ T cells. Am. J. Respir. Crit. Care Med. 2001; 164:2229-2238.
87. Kanehiro A, Lahn M, Makela MJ et al. Requirement for the p75 TNF-α receptor 2 in the regulation of airway hyperresponsiveness by γδ T cells. J. Immunol. 2002;169:4190-4197.
88. Broide DH, Campbell K, Gifford T, Sriramarao P. Inhibition of eosinophilic inflammation in allergen-challenged, IL-1 receptor type 1-deficient mice is associated with reduced eosinophil rolling and adhesion on vascular endothelium. Blood 2000;95:263-269.
89. Chensue SW, Lukacs NW, Yang TY et al. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J. Exp. Med. 2001;193:573-584.
90. Bates J, Irvin C, Brusasco V et al. The use and misuse of Penh in animal models of lung disease. Am. J. Respir. Cell Mol. Biol. 2004;31:373-374.
91. Sly PD, Turner DJ, Collins RA, Hantos Z. Penh is not a validated technique for measuring airway function in mice. Am. J. Respir. Crit. Care Med. 2005;172:256.
92. Hellings PW, Kasran A Liu Z et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 2003;28:42-50.
93. He R, Oyoshi MK, Jin H, Geha RS. Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge. Proc. Natl. Acad. Sci. U. S. A. 2007;104:15817-15822.
94. Schnyder-Candrian S, Togbe D, Couillin I et al. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 2006;203:2715-2725.
95. Hurst SD, Muchamuel T, Gorman DM et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL25. J. Immunol. 2002;169:443-453.
96. + T cells in alphabeta-T cell receptor transgenic mice. Am. J. Respir. Crit. Care Med. 2000;161:1340-1348.
97. Wilder JA, Collie DD, Bice DE, Tesfaigzi Y, Lyons CR, Lipscomb MF. Ovalbumin aerosols induce airway hyperreactivity in naive DO11.10 T cell receptor transgenic mice without pulmonary eosinophilia or OVA-specific antibody. J. Leukoc. Biol. 2001;69:538-547.
98. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 1998;76:34-40.
99. Nakae S, Suto H, Berry GJ, Galli SJ. Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 2007;109:3640-3648.
100. Nakae S, Ho LH, Yu M et al. Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. J. Allergy Clin. Immunol. 2007;120:48-55.
101. van den Berg A, Kuiper M, Snoek M et al. Interleukin-17 induces hyperresponsive interleukin-8 and interleukin-6 production to tumor necrosis factor-alpha in structural lung cells. Am. J. Respir. Cell Mol. Biol. 2005;33:97-104.
102. Shen F, Ruddy MJ, Plamondon P, Gaffen SL. Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-α-induced genes in bone cells. J. Leukoc. Biol. 2005;77:388-399.
103. Hartupee J, Liu C, Novotny M, Li X, Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 2007;179:4135-4141.
104. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-α increases airway responsiveness and sputum neutrophilia in normal human subjects. Am. J. Respir. Crit. Care Med. 1995;152:76-80.
105. Basyigit I, Yildiz F, Ozkara SK, Boyaci H, Ilgazli A. Inhaled corticosteroid effects both eosinophilic and non-eosinophilic inflammation in asthmatic patients. Mediators Inflamm. 2004;13:285-291.
106. Bradding P, Roberts JA, Britten KM et al. Interleukin-4, -5, and -6 and tumor necrosis factor-α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 1994;10:471-480.
107. Howarth PH, Babu KS, Arshad HS et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:1012-1018.
108. Babu KS, Davies DE, Holgate ST. Role of tumor necrosis factor α in asthma. Immunol. Allergy Clin. North. Am. 2004;24:583-597, v-vi.
109. Berry MA Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N. Engl. J. Med. 2006;354:697-708.
110. Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir. Med. 2005;99:1175-1182.
111. Cohn L, Homer RJ, Marinov A, Rankin J, Bottomly K. Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J. Exp. Med. 1997;186:1737-1747.
112. Liang SC, Long AJ, Bennett F et al. An IL-17F/ A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J. Immunol. 2007;179:7791-7799.
113. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 2002;295:338-342.
114. Fujiwara M, Hirose K, Kagami S et al. T-bet inhibits both TH2 cell-mediated eosinophil recruitment and TH17 cell-mediated neutrophil recruitment into the airways. J. Allergy Clin. Immunol. 2007;119:662-670.
115. Scheerens H, Buckley TL, Muis TL et al. Long-term topical exposure to toluene diisocyanate in mice leads to antibody production and in vivo airway hyperresponsiveness three hours after intranasal challenge. Am. J. Respir. Crit. Care Med. 1999;159:1074-1080.
116. Matheson JM, Lemus R, Lange RW, Karol MH, Luster MI. Role of tumor necrosis factor in toluene diisocyanate asthma. Am. J. Respir. Cell Mol. Biol. 2002;27:396-405.
117. Herrick CA, Xu L, Wisnewski AV, Das J, Redlich CA, Bottomly K. A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge. J. Allergy Clin. Immunol. 2002;109:873-878.
118. Herrick CA, Das J, Xu L, Wisnewski AV, Redlich CA, Bottomly K. Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: genetic control of TH2-induced lung inflammation. J. Allergy Clin. Immunol. 2003;111:1087-1094.
119. van Houwelingen AH, Kool M, de Jager SC et al. Mast cell-derived TNF-α primes sensory nerve endings in a pulmonary hypersensitivity reaction. J. Immunol. 2002;168:5297-5302.
120. Kraneveld AD, van der Kleij HP, Kool M et al. Key role for mast cells in nonatopic asthma. J. Immunol. 2002;169:2044-2053.
121. Kim SR, Lee KS, Park SJ et al. PTEN down-regulates IL-17 expression in a murine model of toluene diisocyanate-induced airway disease. J. Immunol. 2007;179:6820-6829.
122. Klemens C, Rasp G, Jund F et al. Mediators and cytokines in allergic and viral-triggered rhinitis. Allergy Asthma Proc. 2007;28:434-441.
123. Miyoshi T, Fukagawa K, Shimmura S et al. Interleukin-8 concentrations in conjunctival epithelium brush cytology samples correlate with neutrophil, eosinophil infiltration, and corneal damage. Cornea 2001;20:743-747.
124. Galatowicz G, Ajayi Y, Stern ME, Calder VL. Ocular antiallergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin. Exp. Allergy 2007;37:1648-1656.
125. Sicherer SH, Eigenmann PA, Sampson HA. Clinical features of food protein-induced enterocolitis syndrome. J. Pediatr. 1998;133:214- 219.
126. van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr. Opin. Allergy Clin. Immunol. 2007;7:374-381.
127. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 1998;111:645-649.
128. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-γ and TNF-α. J. Immunol. 1999;162:494-502.
129. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma-and interleukin-4-induced activation of human keratinocytes. J. Invest. Dermatol. 2000;115:81-87.
130. Homey B, Dieu-Nosjean MC, Wiesenborn A et al. Upregulation of macrophage inflammatory protein-3α/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 2000;164:6621-6632.
131. Toda M, Leung DY, Molet S et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J. Allergy Clin. Immunol. 2003;111:875-881.
132. Kimber I, Dearman RJ. Allergic contact dermatitis: the cellular effectors. Contact Dermatitis 2002;46:1-5.
133. + T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur. J. Immunol. 1995;25:3006-3010.
134. + type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity. J. Immunol. 2000;165: 6783-6790.
135. + T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse. Int. Immunol. 2004;16:685-695.
136. Saulnier M, Huang S, Aguet M, Ryffel B. Role of interferon-γ in contact hypersensitivity assessed in interferon-γ receptor-deficient mice. Toxicology 1995;102:301-312.
137. Nakae S, Komiyama Y, Narumi S et al. IL-1-induced tumor necrosis factor-α elicits inflammatory cell infiltration in the skin by inducing IFN-γ-inducible protein 10 in the elicitation phase of the contact hypersensitivity response. Int. Immunol. 2003;15:251-260.
138. Reeve VE, Bosnic M, Nishimura N. Interferon-γ is involved in photoimmunoprotection by UVA (320-400 nm) radiation in mice. J. Invest. Dermatol. 1999;112:945-950.
139. Dhabhar FS, Satoskar AR, Bluethmann H, David JR, McEwen BS. Stress-induced enhancement of skin immune function: A role for γ interferon. Proc. Natl. Acad. Sci. U. S. A. 2000;97:2846-2851.
140. Lu B, Ebensperger C, Dembic Z et al. Targeted disruption of the interferon-γ receptor 2 gene results in severe immune defects in mice. Proc. Natl. Acad. Sci. U. S. A. 1998;95:8233-8238.
141. Berg DJ, Leach MW, Kuhn R et al. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J. Exp. Med. 1995;182:99-108.
142. Traidl C, Jugert F, Krieg T, Merk H, Hunzelmann N. Inhibition of allergic contact dermatitis to DNCB but not to oxazolone in interleukin-4-deficient mice. J. Invest. Dermatol. 1999;112:476-482.
143. Dieli F, Sireci G, Scire E, Salerno A, Bellavia A. Impaired contact hypersensitivity to trinitrochlorobenzene in interleukin-4-deficient mice. Immunology 1999;98:71-79.
144. Weigmann B, Schwing J, Huber H et al. Diminished contact hypersensitivity response in IL-4 deficient mice at a late phase of the elicitation reaction. Scand. J. Immunol. 1997;45:308-314.
145. Herrick CA, Xu L, McKenzie AN, Tigelaar RE, Bottomly K. IL-13 is necessary, not simply sufficient, for epicutaneously induced Th2 responses to soluble protein antigen. J. Immunol. 2003;170:2488-2495.
146. Yokozeki H, Ghoreishi M, Takagawa S et al. Signal transducer and activator of transcription 6 is essential in the induction of contact hypersensitivity. J. Exp. Med. 2000;191:995-1004.
147. + IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J. Immunol. 2006;177:6852- 6858.